



Case Docket No.: GENENT.061CP2
Date: September 17, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Lasky et al.
Appl. No. : 09/068,377
Filed : May 8, 1998
For : TYROSINE
PHOSPHORYLATED
CLEAVAGE FUROW-
ASSOCIATED PROTEINS
(PSTPIPs)
Examiner : S. Rawlings
Group Art Unit : 1645

I hereby certify that this correspondence and all
marked attachments are being deposited with the
United States Postal Service as first class mail in
an envelope addressed to: Assistant Commissioner
for Patents, Washington, D.C. 20231, on

September 17, 2001
(Date)

Ginger R. Dreger, Registration No. 33,055


TRANSMITTAL LETTER

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) Sequence Submission Statement.
- (X) Sequence Listing in paper form.
- (X) Sequence Listing in computer readable form.
- (X) A Copy of the Notice to Comply.
- (X) The Commissioner is hereby authorized to charge any additional fees that may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Ginger R. Dreger
Registration No. 33,055
Attorney of Record

GP1645 Box seq
PATENT
RECEIVED
SEP 25 2001
TECH CENTER 1600/2900
#25
JW
9/28/01

09/068377



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/068,377	LASKY	L P1066P2

5611
GINGER R DREGER
GENENTECH INCORPORATED
1 DNA WAY
SOUTH SAN FRANCISCO CA 94080-4990

INTERNATIONAL APPLICATION NO.

PCT/US98/01774

I.A. FILING DATE PRIORITY DATE

01/30/98 02/07/97

DATE MAILED: 07/22/99

**NOTIFICATION OF ACCEPTANCE OF APPLICATION UNDER 35 U.S.C. 371
AND 37 CFR 1.494 OR 1.495**

1. The applicant is hereby advised that the United States Patent and Trademark Office in its capacity as ☐ a Designated Office (37 CFR 1.494), ☒ an Elected Office (37 CFR 1.495), has determined that the above identified international application has met the requirements of 35 U.S.C. 371, and is **ACCEPTED** for national patentability examination in the United States Patent and Trademark Office.

2. The United States Application Number assigned to the application is shown above and the relevant dates are:

08 MAY 1999

35 U.S.C. 102(e) DATE

08 MAY 1999

DATE OF RECEIPT OF
35 U.S.C. 371 REQUIREMENTS

A Filing Receipt (PTO-103X) will be issued for the present application in due course. **THE DATE APPEARING ON THE FILING RECEIPT AS THE "FILING DATE" IS THE DATE ON WHICH THE LAST OF THE 35 U.S.C. 371(C) REQUIREMENTS HAS BEEN RECEIVED IN THE OFFICE. THIS DATE IS SHOWN ABOVE.** *The filing date of the above identified application is the international filing date of the international application (Article 11(3) and 35 U.S.C. 363).* Once the Filing Receipt has been received, send all correspondence to the Group Art Unit designated thereon.

3. ☐ A request for immediate examination under 35 U.S.C. 371(f) was received on _____ and the application will be examined in turn.

4. The following items have been received:

- ☒ U.S. Basic National Fee.
- ☒ Copy of the international application in:
 - ☐ a non-English language.
 - ☒ English.
- ☒ Translation of the international application into English.
- ☒ Oath or Declaration of inventor(s) for DO/EO/US.
- ☐ Copy of Article 19 amendments. ☐ Translation of Article 19 amendments into English.
The Article 19 amendments ☐ have ☐ have not been entered.
- ☒ The International Preliminary Examination Report in English and its Annexes, if any.
- ☒ Copy of the Annexes to the International Preliminary Examination Report (IPER).
☒ Translation of Annexes to the IPER into English.
The Annexes ☒ have ☐ have not been entered.
- ☐ Preliminary amendment(s) filed _____ and _____.
- ☐ Information Disclosure Statement(s) filed _____ and _____.
- ☐ Assignment document.
- ☒ Power of Attorney and/or Change of Address.
- ☐ Substitute specification filed _____.
- ☐ Statement Claiming Small Entity Status.
- ☐ Priority Document.
- ☒ Copy of the International Search Report ☒ and copies of the references cited therein.
- ☐ Other:

Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above. (37 CFR 1.5)

FORM PCT/DO/EO/903 (December 1997)

Telephone: (703)

Patent Mail Room
National Sign Processing
Patent Specialist
(703) 305-3556


RECEIVED

SEP 25 2001

TECH CENTER 1600/2900

PATENT

SEQUENCE.061CP2



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lasky et al.) Group Art Unit: 1642
Appl. No. : 09/068,377) I hereby certify that this correspondence and marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on
Filed : May 8, 1998)
For : TYROSINE) September 17, 2001
PHOSPHORYLATED) (Date)
CLEAVAGE FURROW-)
ASSOCIATED PROTEINS)
(PSTPIPs))
Examiner : S. Rawlings)
Ginger R. Dreger, Reg. No. 33,055

SEQUENCE SUBMISSION STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This is in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, included with the Advisory Action mailed on August 22, 2001.


I hereby state that the amendments, made in accordance with 37 C.F.R. § 1.825(a), included herewith, are supported in the application and that the Sequence Listing does not include new matter.

I hereby state that the computer readable form, submitted in accordance with 37 C.F.R. § 1.825(b), is the same as the paper form of the Sequence Listing.

Respectfully submitted,
KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: September 17, 2001

By: [Signature]
Ginger R. Dreger, Registration No. 33,055
Attorney of Record
620 Newport Center Drive, Sixteenth Floor
Newport Beach, CA 92660
(415) 954-4114



Notice to Comply

Application No.

09/068,377

Examiner

Stephen L. Rawlings, Ph.D.

Applicant(s)

LASKY ET AL.

Art Unit

1642

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

RECEIVED
SEP 25 2001
TECH CENTER 1600/2900